doi: 10.1128/AEM.72.3.1729-1738.2006 93 IslamKBMSFukiyaSHagioMFujiiNIshizukaSOokaTet al
J Nutr Biochem
Anyone receiving retatrutide within a clinical trial should seek prompt medical advice from their trial team if they experience any of the following: Persistent or severe vomiting that prevents adequate fluid or food intake Signs of dehydration , including dizziness, reduced urination, or extreme thirst Severe or persistent abdominal pain , which may rarely indicate pancreatitis or a gallbladder problem Right upper quadrant pain, fever, or jaundice , which may suggest acute gallbladder disease (cholelithiasis or cholecystitis) a recognised risk with GLP-1-based therapies and with rapid weight loss [11] [12] Symptoms of hypoglycaemia (particularly if taking concomitant insulin or sulphonylureas), such as shakiness, sweating, or confusion Injection site reactions that are worsening, infected, or not resolving Retatrutide has not been studied in pregnancy or breastfeeding, and use during pregnancy or whilst breastfeeding is not recommended until safety data are available
Always ask your doctor before you begin any new treatment
Regular reviews of all medications by healthcare providers, including nephrologists and pharmacists, are vital
If the FDA changes guidance, restricts, or removes access to any compounded preparation, Vesta will discontinue that preparation in alignment with federal regulation
